Skip to content

Effects of special probiotic strains on the diversity, function and metabolites of intestinal flora in H. Pylori patients

Study on raw material formula of stomach protection (anti-Helicobacter pylori) probiotics

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200063749
Enrollment
Unknown
Registered
2022-09-15
Start date
2023-06-20
Completion date
Unknown
Last updated
2023-07-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

H. pylori infection

Interventions

Experimental group:BQT for 14 days and supplemented with probiotics
Control group:BQT for 14 days and supplemented with placebo

Sponsors

Shanghai Tenth People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Positive rapid urease test and 13C-urea breath test (13C-UBT); 2. Age 18-65 years; 3. Did not use antacids or gastric mucosal protection drugs, antibiotics or probiotics in the past month; 4. During the study period, any special dietary intervention, especially products containing probiotics, cannot be carried out; 5. The legal representative or guardian of the patient voluntarily agrees and signs the informed consent form, and can abide by the research protocol during the research period.

Exclusion criteria

Exclusion criteria: 1. Patients with any of the following diseases were excluded from the study: history of gastrectomy, previous Helicobacter pylori eradication therapy, peptic ulcer or other upper gastrointestinal lesions, gastrointestinal malignancies; 2. Contraindications or allergic reactions to the study drugs in the past; 3. Use of antacids or gastric mucosal protection drugs, antibiotics or probiotics in the past month; 4. Those who have a recent history of glucocorticoids and immune preparations; 5. Pregnant or lactating women; 6. History of intolerance or allergy to probiotics; 7. Patients who cannot express their subjective feelings correctly and cannot cooperate; 8. Participate in another clinical study within 6 months before the start of the trial.

Design outcomes

Primary

MeasureTime frame
Quantitative subgenomic alterations in bacterial genes and species;Intestinal metabolites;

Secondary

MeasureTime frame
Markers of inflammation;Intestinal barrier function;Gastrointestinal symptom score;13C-urea respiration test;Food Frequency Questionnaire;

Countries

China

Contacts

Public ContactHan Ting

Shanghai Tenth People's Hospital

253255849@qq.com+86 189 1768 3618

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026